Ma et al. Journal of Experimental & Clinical Cancer Research 2010, 29:85 http://www.jeccr.com/content/29/1/85 Received: 18 March 2010 Accepted: 30 June 2010 Published: 30 June 2010 JT©oh2uis0rnia1sr0taliMnoclfeaOEiepxsteanvrl;iaAmilcaebntleaslfa&reotBCmciol:neMhicdteaisdplt:rC/iabewuncwterwadRl.juLetsncdeare.crothm2e0/ct1eo0rn,mt2es9no:8tf/52th9e/1C/8re5ativeCommonsAt ributionLicense(ht p:/ creativecommons.org/licenses/by/2.0),whichpermitsunrestricteduse,distribution,andreproductioninanymedium,providedtheoriginalworkisproperlycited. References 1. Ni X, Gu S, Dai J, Cheng H, Guo L, Li L, Ji C, Xie Y, Ying K, Mao Y: Isolation and characterization of a novel human NM23-H1B gene, a different transcript of NM23-H1. J Hum Genet 2003, 48(2):96-100. 2. Wozney JM: The bone morphogenetic protein family: multifunctional cellular regulators in the embryo and adult. Eur J Oral Sci 1998, 106(Suppl 1):160-166. 3. Miyazono K, Kusanagi K, Inoue H: Divergence and convergence of TGF- beta/BMP signaling. J Cell Physiol 2001, 187(3):265-276. 4. Ghosh-Choudhury N, Ghosh-Choudhury G, Celeste A, Ghosh PM, Moyer M, Abboud SL, Kreisberg J: Bone morphogenetic protein-2 induces cyclin kinase inhibitor p21 and hypophosphorylation of retinoblastoma protein in estradiol-treated MCF-7 human breast cancer cells. Biochim Biophys Acta 2000, 1497(2):186-196. 5. Dumont N, Arteaga CL: A kinase-inactive type II TGFbeta receptor impairs BMP signaling in human breast cancer cells. Biochem Biophys Res Commun 2003, 301(1):108-112. 6. Ghosh-Choudhury N, Woodruff K, Qi W, Celeste A, Abboud SL, Ghosh Choudhury G: Bone morphogenetic protein-2 blocks MDA MB 231 human breast cancer cell proliferation by inhibiting cyclin-dependent kinase-mediated retinoblastoma protein phosphorylation. Biochem Biophys Res Commun 2000, 272(3):705-711. 7. Tada A, Nishihara T, Kato H: Bone morphogenetic protein 2 suppresses the transformed phenotype and restores actin microfilaments of human lung carcinoma A549 cells. Oncol Rep 1998, 5(5):1137-1140. 8. Langenfeld EM, Bojnowski J, Perone J, Langenfeld J: Expression of bone morphogenetic proteins in human lung carcinomas. Ann Thorac Surg 2005, 80(3):1028-1032. 9. Langenfeld EM, Calvano SE, Abou-Nukta F, Lowry SF, Amenta P, Langenfeld J: The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis 2003, 24(9):1445-1454. 10. Langenfeld EM, Langenfeld J: Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res 2004, 2(3):141-149. 11. Langenfeld EM, Kong Y, Langenfeld J: Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5. Oncogene 2006, 25(5):685-692. 12. Kumagai T, Tomari K, Shimizu T, Takeda K: Alteration of gene expression in response to bone morphogenetic protein-2 in androgen-dependent human prostate cancer LNCaP cells. Int J Mol Med 2006, 17(2):285-291. 13. Orui H, Imaizumi S, Ogino T, Motoyama T: Effects of bone morphogenetic protein-2 on human tumor cell growth and differentiation: a preliminary report. J Orthop Sci 2000, 5(6):600-604. 14. Horvath LG, Henshall SM, Kench JG, Turner JJ, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, et al.: Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate 2004, 59(3):234-242. 15. Hardwick JC, Van Den Brink GR, Bleuming SA, Ballester I, Van Den Brande JM, Keller JJ, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP: Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology 2004, 126(1):111-121. 16. Soda H, Raymond E, Sharma S, Lawrence R, Cerna C, Gomez L, Timony GA, Von Hoff DD, Izbicka E: Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units. Anticancer Drugs 1998, 9(4):327-331. 17. Urist MR: Bone: formation by autoinduction. Science 1965, 150(698):893-899. 18. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA: Novel regulators of bone formation: molecular clones and activities. Science 1988, 242(4885):1528-1534. 19. Waite KA, Eng C: BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels. Hum Mol Genet 2003, 12(6):679-684. 20. Wen XZ, Miyake S, Akiyama Y, Yuasa Y: BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells. Biochem Biophys Res Commun 2004, 316(1):100-106. 21. Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, Schwarz EM, Huard J, Lieberman JR: Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 2006, 38(2):154-166. Page 6 of 6 22. Kiyozuka Y, Nakagawa H, Senzaki H, Uemura Y, Adachi S, Teramoto Y, Matsuyama T, Bessho K, Tsubura A: Bone morphogenetic protein-2 and type IV collagen expression in psammoma body forming ovarian cancer. Anticancer Res 2001, 21(3B):1723-1730. 23. Le Page C, Ouellet V, Madore J, Ren F, Hudson TJ, Tonin PN, Provencher DM, Mes-Masson AM: Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer. Br J Cancer 2006, 94(3):436-445. doi: 10.1186/1756-9966-29-85 Cite this article as: Ma et al., Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prog- nosis of ovarian cancer patients Journal of Experimental & Clinical Cancer Research 2010, 29:85